Sudhirdas R Prayaga

7291483, Nov 6, 2007

Dec 30, 2004

11/027948

Richard A. Shimkets - West Haven CT, US
Sudhirdas K. Prayaga - Chesterfield MO, US

CuraGen Corporation - New Haven CT

C07K 14/50
C12N 1/21
C12N 5/10
C12N 15/18
C12N 15/63

435 691, 435 694, 4353201, 435243, 435325, 536 235, 530399, 530412

The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-GX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.

20050003370, Jan 6, 2005

Sep 7, 2004

10/691165

Sudhirdas Prayaga - Chesterfield MO, US
Raymond Taupier - East Haven CT, US
Raj Bandaru - New Haven CT, US

C12Q001/68
C07H021/04
C07K014/705

435006000, 435069100, 435320100, 435325000, 530350000, 536023500

Disclosed herein are novel human nucleic acid sequences. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving these novel nucleic acids and proteins.

6600019, Jul 29, 2003

Jan 4, 2001

09/755665

Sudhirdas K. Prayaga - OFallon MO
Kumud Majumder - Stamford CT
Bruce Taillon - Middletown CT
Steven Kurt Spaderna - Berlin CT
Kimberly Spytek - New Haven CT
John MacDougall - New Haven CT

CuraGen Corporation - New Haven CT

C07K 1447

530350, 435975, 514 8, 514 12, 530395, 530397, 530398

The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

20170190750, Jul 6, 2017

Jan 13, 2017

15/406535

- Baton Rouge LA, US
Sudhirdas K. Prayaga - Dardenne Prairie MO, US

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College - Baton Rouge LA

C07K 14/47
A61K 39/35
G01N 33/68
C07K 16/18

A peptide (Peptide-1) based on the C-terminal of Equine CC10 has been discovered that can be used as a vaccine to protect horses from respiratory airway obstruction (RAO), Antibodies to Peptide-1 may also be administered for short-term passive immunotherapy to RAO-affected horses, and can be used to measure the level of CC10 protein in serum to identify potential RAO horses (horses with reduced CC10). Due to similarities between equine RAO and human asthma, this peptide or its antibodies may also be useful in treatment or prevention of human asthma.

20140105906, Apr 17, 2014

Jun 8, 2012

14/124297

Changaram S. Venugopal - Prairieville LA, US
Sudhirdas K. Prayaga - Dardenne Prairie MO, US

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College - Baton Rouge LA

C07K 14/47
G01N 33/68
C07K 16/18

4241391, 530326, 4241851, 5303879, 435 792, 4353201, 4241841

A peptide (Peptide-1) based on the C-terminal of Equine CC10 has been discovered that can be used as a vaccine to protect horses from respiratory airway obstruction (RAO). Antibodies to Peptide-1 may also be administered for short-term passive immunotherapy to RAO-affected horses, and can be used to measure the level of CC10 protein in serum to identify potential RAO horses (horses with reduced CC10). Due to similarities between equine RAO and human asthma, this peptide or its antibodies may also be useful in treatment or prevention of human asthma.

20050208514, Sep 22, 2005

Nov 3, 2004

10/980659

John Alsobrook - Madison CT, US
Ferenc Boldog - North Haven CT, US
Michael Jeffers - Branford CT, US
William LaRochelle - Madison CT, US
Denise Lepley - Hartford CT, US
Henri Lichenstein - Guilford CT, US
Richard Shimkets - Guilford CT, US
Meijia Yang - Scituate MA, US
Marie Ruiz-Martinez - Bethany CT, US
Galina Chernaya - Madison CT, US
Muralidhara Padigaru - Malad Mumbai, IN
Sudhirdas Prayaga - O'Fallon MO, US
Mei Zhong - Branford CT, US

C12Q001/68
A61K038/18
C07K014/50

435006000, 435069100, 435320100, 435325000, 530399000, 514012000, 536023500

The present invention generally relates to nucleic acids, proteins, and antibodies. The invention relates more particularly to nucleic acid molecules, proteins, and antibodies of Fibroblast Growth Factor-20 (FGF-20), or its fragments, derivatives, variants, homologs, analogs, or a combination thereof.

20060094647, May 4, 2006

Nov 6, 2001

09/992840

Michael Jeffers - Branford CT, US
Richard Shimkets - Guilford CT, US
Sudhirdas Prayaga - O'Fallon MO, US
Ferenc Boldog - North Haven CT, US
Meijia Yang - East Lyme CT, US
Catherine Burgess - Wethersfield CT, US
Elma Fernandes - Branford CT, US
Beth Rittman - Colchester CT, US
Juliette Shimkets - Guilford CT, US
William LaRochelle - Madison CT, US
Henri Lichenstein - Guilford CT, US

A61K 38/17

514012000

The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotide sequences and the FGF-CX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.

20050287564, Dec 29, 2005

May 10, 2005

11/126427

Linda Gorman - Branford CT, US
Richard Shimkets - Guilford CT, US
Carol Pena - New Haven CT, US
Valerie Gerlach - East Brunswick NJ, US
Kumud Majumder - Upper Saddle River NJ, US
Sudhirdas Prayaga - O'Fallon MO, US
Catherine Burgess - Wethersfield CT, US

C12Q001/68
A61K038/17
C07K014/47
C07K016/18
C07H021/04

435006000, 435069100, 435320100, 435325000, 530350000, 530388100, 536023500, 514012000

Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.